Back to Search Start Over

Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia

Authors :
Ravandi, Farhad
Bashey, Asad
Foran, James
Stock, Wendy
Mawad, Raya
Short, Nicholas
Yilmaz, Musa
Kantarjian, Hagop
Odenike, Olatoyosi
Patel, Anand
Garcha, Raman
Ainsworth, William Barrett
Clynes, Raphael
Kanodia, Jitendra
Ding, Ying
Li, Huajiang
Kye, Steve
Mims, Alice
Source :
Blood Advances; November 2023, Vol. 7 Issue: 21 p6492-6505, 14p
Publication Year :
2023

Abstract

•A dose-optimized schedule of priming, step-up, and target vibecotamab doses mitigated CRS while achieving response.•Low blast-count AML and low PD-1 expression on CD4+and CD8+T cells were associated with response to vibecotamab.

Details

Language :
English
ISSN :
24739529 and 24739537
Volume :
7
Issue :
21
Database :
Supplemental Index
Journal :
Blood Advances
Publication Type :
Periodical
Accession number :
ejs63952302
Full Text :
https://doi.org/10.1182/bloodadvances.2023010956